Meta-analy
Internal Medicine
2022-11-30

Meta-analysis suggests extended thromboprophylaxis reduces risk of thrombosis and all-cause mortality in post-discharge patients with COVID-19

In post-discharge patients with coronavirus disease 2019 (COVID-19) at high risk of thromboembolism, extended thromboprophylaxis, primarily prophylactic use of anticoagulants for < 35 days, can significantly reduce the risk of thrombosis and all-cause mortality without increasing the risk of major bleeding events, according to a meta-analysis published in Thrombosis Research.  “This study is the first, to the best of our knowledge, to provide a comprehensive investigation of the effectiveness and safety of extended thromboprophylaxis in post-discharge patients with COVID-19 based on evidenc...

Fulminant
Internal Medicine
2022-11-29

Fulminant Myocarditis and Acute Appendicitis after COVID-19 Vaccination

A 19-year-old Japanese man was hospitalized for cardiogenic shock 28 days after receiving a second d...

Blood Pres
Internal Medicine
2022-11-25

Blood Pressure Responses During Exercise: Physiological Correlates and Clinical Implications

BACKGROUND Abnormal blood pressure (BP) responses to exercise can predict adverse cardiovascular out...

Videos from category: Cardiology

A fresh lo
11:34

A fresh look at pulmonary hypertension: practical takeaways for patient management

ESC 2022
Facing ant
11:52

Facing anticoagulation dilemmas in venous thromboembolism

ESC 2022
Influenza
5:14

Influenza Vaccine Among Patients with Acute Coronary Syndromes: the VIP-ACS trial

ESC 2022
The import
6:20

The importance of optimal RAASi therapy in heart failure

ESC 2022

Videos from category: Dermatology

New pathog
7:31

New pathogenic insights in chronic urticaria

EADV Symposium 2022
Long-term
8:46

Long-term efficacy and safety of ixekizumab

Treatment
8:50

Treatment options of chronic urticaria

EADV Symposium 2022
Psoriasis
6:51

Psoriasis is a systemic disease

EADV 2020

Videos from category: Diabetology

Targeting
9:22

Targeting CV risk factors with GLP-1 RAs in people with obesity

EASD 2022
Once weekl
7:36

Once weekly insulin: The ONWARDS 2 study

EASD 2022
Is HFpEF h
20:42

Is HFpEF hiding in your practice? Key messages of the DELIVER study: Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

EASD 2022
Semaglutid
10:59

Semaglutide 2.4 mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity

EASD 2022

Videos from category: Gastroenterology

Duodenal m
11:01

Duodenal mucosal resurfacing shown to discontinue insulin treatment in majority of type 2 diabetes patients and aid weight loss

UEG 2020
Allergy-re
7:48

Allergy-related diseases and IBS

UEG 2020
A Next-Gen
3:06

A Next-Generation, Dual-Action Anti-Integrin Therapy for IBD

ECCO 2020
How to seq
2:20

How to sequence advanced therapies in IBD

ECCO 2020

Videos from category: Hematology

Risks for
5:01

Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology

ASH 2021
Novelties
12:44

Novelties in the treatment of multiple myeloma 2021

ASH 2021
Novelties
8:35

Novelties in the treatment of myelofibrosis and polycythemia vera 2021

ASH 2021
Antibody R
7:02

Antibody Response to Vaccination with Myeloid and Lymphoid Neoplasms

ASH 2021

Videos from category: Internal Medicine

The Journe
3:15

The Journey to Address Unmet Needs Across all Haemophilia Indications

ISTH 2022
Anticoagul
8:47

Anticoagulant Advancements for VTE in Children

ISTH 2022
Clinical C
6:18

Clinical Challenges in Patients with Venous Thromboembolism

ISTH 2022
Good pract
19:37

Good practice statements for antithrombotic therapy in the management of COVID-19

ISTH 2022

Videos from category: Oncology

Primary re
5:15

Primary results of the phase 3 KEYNOTE-412 study

ESMO 2022
Treatment
8:60

Treatment with tumor-infiltrating lymphocytes versus ipilimumab for advanced melanoma

ESMO 2022
The IPSOS
6:13

The IPSOS trial

ESMO 2022
Results fr
5:010

Results from the phase 3 PARADIGM trial

ASCO 2022

Videos from category: Psychiatry

Novel Phar
8:13

Novel Pharmacotherapeutic Strategies for Regaining Control over Alcohol Intake in Alcohol Use Disorder

EPA 2021
Obstetric
6:010

Obstetric Complications: The Forgotten Risk Factor for Schizophrenia

EPA 2021
Consequenc
7:54

Consequences of COVID-19 Outbreak on Mental Health

EPA 2021
Meeting th
15:41

Meeting the challenges of schizophrenia care during the COVID-19 pandemic

EPA 2021

Videos from category: Respiratory

Choices in
10:06

Choices in asthma and COPD care: How to maximize outcomes for patients

ERS 2022
The digita
11:38

The digital age: The future of respiratory medicine

ERS 2021
Pulmonary
7:05

Pulmonary hypertension and interstitial pulmonary fibrosis

ERS 2021
ERS/EAACI
8:50

ERS/EAACI statement on adherence to international adult asthma guidelines

ERS 2021

Videos from category: Urology

Balancing
13:20

Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma studies

EAU 2021

Suggested videos

By Author
By Topic
By Congress
Search by Scientific Content
Search by Congress
Search:
Date
Filters:
Targeting
9:22
Title Description

Targeting CV risk factors with GLP-1 RAs in people with obesity

Presenter: A. Michael Lincoff
Diabetology
EASD 2022
Once weekl
7:36
Title Description

Once weekly insulin: The ONWARDS 2 study

Presenter: Tina Vilsbøll
Diabetology
EASD 2022
Is HFpEF h
20:42
Title Description

Is HFpEF hiding in your practice? Key messages of the DELIVER study: Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Presenter: Silvio Inzucchi
Diabetology
EASD 2022
Semaglutid
10:59
Title Description

Semaglutide 2.4 mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity

Presenter: Timothy Garvey
Diabetology
EASD 2022
Semaglutid
7:29
Title Description

Semaglutide 2.4 mg improved glucose metabolism and reverted prediabetes to normoglycaemia in adults with overweight or obesity vs liraglutide 3.0 mg

Diabetology
EASD 2022
Primary re
5:15
Title Description

Primary results of the phase 3 KEYNOTE-412 study

Presenter: Jean-Pascal Machiels
Oncology
ESMO 2022
Let’s talk
8:42
Title Description

Let’s talk about CGM evidence: Using basal insulins in T1D in daily life and when exercising

Presenter: Othmar Moser
Diabetology
EASD 2022
Treatment
8:60
Title Description

Treatment with tumor-infiltrating lymphocytes versus ipilimumab for advanced melanoma

Presenter: John Haanen
Oncology
ESMO 2022
Effect of
5:55
Title Description

Effect of liraglutide on muscle fat infiltration in adults with overweight or obesity

Presenter: Ambarish Pandey
Diabetology
EASD 2022
The IPSOS
6:13
Title Description

The IPSOS trial

Presenter: Siow Ming Lee
Oncology
ESMO 2022
Choices in
10:06
Title Description

Choices in asthma and COPD care: How to maximize outcomes for patients

Presenter: Charlotte Suppli Ulrik
Respiratory
ERS 2022
A fresh lo
11:34
Title Description

A fresh look at pulmonary hypertension: practical takeaways for patient management

Presenter: John Gerard Coghlan
Cardiology
ESC 2022
Facing ant
11:52
Title Description

Facing anticoagulation dilemmas in venous thromboembolism

Presenter: Ingrid Pabinger
Cardiology
ESC 2022
Influenza
5:14
Title Description

Influenza Vaccine Among Patients with Acute Coronary Syndromes: the VIP-ACS trial

Presenter: Remo H. M. Furtado
Cardiology
ESC 2022
The import
6:20
Title Description

The importance of optimal RAASi therapy in heart failure

Presenter: Dan Atar
Cardiology
ESC 2022
Chronic co
8:45
Title Description

Chronic coronary syndrome: re-thinking treatment management and outcome priorities

Presenter: Athanasios John Manolis
Cardiology
ESC 2022

Lectures

Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
Long-term
8:46
Title Description

Long-term efficacy and safety of ixekizumab

Presenter: Andrew Blauvelt
Dermatology
Paradigm s
12:05
Title Description

Paradigm shift in the early NSCLC? The role of ICIs in the adjuvant treatment

Presenter: Federico Cappuzzo
Oncology
How will t
9:43
Title Description

How will the current therapeutic options change the treatment of RCC in the daily practice?

Presenter: Camillo Porta
Oncology
The role o
5:58
Title Description

The role of immune checkpoint inhibitors and VEGF TKIs in the adjuvant treatment of renal cell carcinoma

Presenter: David F. McDermott
Oncology
Treatment
11:50
Title Description

Treatment intensification in the treatment of prostate cancer

Presenter: Oliver Sartor
Oncology
Pembrolizu
16:35
Title Description

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma

Presenter: Stefan N. Symeonides
Oncology
State of t
6:13
Title Description

State of the art treatment of bladder cancer

Presenter: Matthew R. Zibelman
Oncology
First-line
7:41
Title Description

First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer

Presenter: Ken Kato
Oncology
Treatment
3:27
Title Description

Treatment of iron deficiency in acute and chronic heart failure

Presenter: Piotr Ponikowski
Cardiology
Alcohol se
6:32
Title Description

Alcohol septal ablation in hypertrophic cardiomyopathy: past and future

Presenter: Hubert Seggewiss
Cardiology
The use of
3:35
Title Description

The use of SGLT2 inhibitors in the prevention and treatment of heart failure

Presenter: Petar M. Seferovic
Cardiology
Direct myo
5:15
Title Description

Direct myosin inhibitors in hypertrophic cardiomyopathy: a new era?

Presenter: Iacopo Olivotto
Cardiology
Diagnostic
10:55
Title Description

Diagnostic delay in pulmonary arterial hypertension

Presenter: Barbro Kjellström and Bodil Ivarsson
Clinical I
6:21
Title Description

Clinical Impact of Liraglutide as a Treatment of Obesity

Presenter: Babak Dehestani
Internal Medicine
Associatio
20:17
Title Description

Association of GLP 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events

Presenter: Michael Camilleri
Internal Medicine
Liraglutid
13:26
Title Description

Liraglutide for Weight Management in the Real World

Presenter: Roman Vangoitsenhoven
Cardiology , Diabetology